November 28, 2014
Gilead Sciences K.K. President Yuji Orihara US biotech major Gilead Sciences Inc. officially announced its plan to set foot in the Japanese market in October last year. This year it submitted new drug applications for sofosbuvir and a fixed-dose combination...read more